Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Item
http://www.wikidata.org/entity/Q41448224
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Investigational Janus kinase inhibitors in development for myelofibrosis.Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.Developmental Therapeutics in Myeloproliferative Neoplasms.Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
P2860

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Item
http://www.wikidata.org/entity/Q41448224
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Comprehensive kinase profile o ...... sive Janus kinase 2 inhibitor.
@en
type
label
Comprehensive kinase profile o ...... sive Janus kinase 2 inhibitor.
@en
prefLabel
Comprehensive kinase profile o ...... sive Janus kinase 2 inhibitor.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P478
P50
P577
P698
P932
P356
P1433
P1476
Comprehensive kinase profile o ...... sive Janus kinase 2 inhibitor.
@en
P2093
P2860
P304
P31
P356
P478
P50
P577
P698
P932